Second time lucky for Besponsa UK reimbursement bid

9 August 2018
nice-big-1

Following an appeal from New York’s Pfizer (NYSE: PFE), the UK’s health technology assessor has decided to offer reimbursement for Besponsa (inotuzumab ozogamicin) as a treatment for certain acute lymphoblastic leukaemia (ALL) patients.

The decision means that the antibody-drug conjugate will be routinely available as a second-line treatment for this patient population in England and Wales.

The National Institute for Health and Care Excellence (NICE) had suggested the drug would not be cost-effective, with negative draft guidance in June 2017.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical